{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kuhn M"],"funding":["School of Medicine, Oregon Health and Science University","HHS | NIH | National Institute of General Medical Sciences","OHSU | Knight Cancer Institute, Oregon Health and Science University","NSF | BIO | Division of Biological Infrastructure","Prevent Cancer Foundation","HHS | NIH | NCI | Basic Research Laboratory","American Cancer Society","HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","NIDDK NIH HHS","AGA Research Foundation (American Gastroenterological Association","Lustgarten Foundation","NCI NIH HHS","NIGMS NIH HHS"],"pagination":["G571-G585"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9678429"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["323(6)"],"pubmed_abstract":["Colorectal cancer (CRC) is a leading cause of cancer-related death. There is an urgent need for new methods of early CRC detection and monitoring to improve patient outcomes. Extracellular vesicles (EVs) are secreted, lipid-bilayer bound, nanoparticles that carry biological cargo throughout the body and in turn exhibit cancer-related biomarker potential. RNA binding proteins (RBPs) are posttranscriptional regulators of gene expression that may provide a link between host cell gene expression and EV phenotypes. Insulin-like growth factor 2 RNA binding protein 1 (IGF2BP1/IMP1) is an RBP that is highly expressed in CRC with higher levels of expression correlating with poor prognosis. IMP1 binds and potently regulates tumor-associated transcripts that may impact CRC EV phenotypes. Our objectiv"],"journal":["American journal of physiology. Gastrointestinal and liver physiology"],"pubmed_title":["IMP1/IGF2BP1 in human colorectal cancer extracellular vesicles."],"pmcid":["PMC9678429"],"funding_grant_id":["R01 CA243445","GM124976","F32DK107052","CA243445","R01 DK124369","R01 DK056645","R01 DK109714","F32 DK107052","DK124369","R35 GM124976","DK109714","1936046","DK056645"],"pubmed_authors":["Kuhn M","Liang S","Yang J","Das S","Shah P","Morita M","Blucher A","Williams KN","Armstrong RJ","Parham LR","Mills G","Zhang W","Zhang Y","Favate J","Molugu S","Andres SF","Hamilton KE","Dixon DA","Morgan TK","Preet R"],"additional_accession":[]},"is_claimable":false,"name":"IMP1/IGF2BP1 in human colorectal cancer extracellular vesicles.","description":"Colorectal cancer (CRC) is a leading cause of cancer-related death. There is an urgent need for new methods of early CRC detection and monitoring to improve patient outcomes. Extracellular vesicles (EVs) are secreted, lipid-bilayer bound, nanoparticles that carry biological cargo throughout the body and in turn exhibit cancer-related biomarker potential. RNA binding proteins (RBPs) are posttranscriptional regulators of gene expression that may provide a link between host cell gene expression and EV phenotypes. Insulin-like growth factor 2 RNA binding protein 1 (IGF2BP1/IMP1) is an RBP that is highly expressed in CRC with higher levels of expression correlating with poor prognosis. IMP1 binds and potently regulates tumor-associated transcripts that may impact CRC EV phenotypes. Our objectiv","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-04T09:50:15.496Z","creation":"2025-02-19T01:17:28.672Z"},"accession":"S-EPMC9678429","cross_references":{"pubmed":["36194131"],"doi":["10.1152/ajpgi.00121.2022"]}}